Hashemi N, Araya V, Tufail K, Thummalakunta L, Feyssa E, Azhar A, Niazi M, Ortiz J. An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation. World J Hepatol 2011; 3(7): 198-204
Corresponding Author of This Article
Victor Araya, MD, FACG, AGAF, Division of Hepatology, Center for Liver Disease and Transplantation, Albert Einstein Medical Center, 5501 Old York Road, Klein 509, Philadelphia, PA 19141, United States. firstname.lastname@example.org
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nikroo Hashemi, Victor Araya, Kashif Tufail, Eyob Feyssa, Ashaur Azhar, Mumtaz Niazi, Laxmi Thumma-lakunta, Division of Hepatology, Center for Liver Disease and Transplantation, Albert Einstein Medical Center, Philadelphia, PA 19141, United States
Jorge Ortiz, Division of Transplant Surgery, Center for Liver Disease and Transplantation, Albert Einstein Medical Center, Philadelphia, PA 19141, United States
Author contributions: Hashemi N, Araya V, Tufail K,Feyssa E, Azhar A, Niazi M and Ortiz J designed the study and collected the data; Hashemi N, Araya V, Tufail K and Thummalakunta L wrote the paper.
Correspondence to: Victor Araya, MD, FACG, AGAF, Division of Hepatology, Center for Liver Disease and Transplantation, Albert Einstein Medical Center, 5501 Old York Road, Klein 509, Philadelphia, PA 19141, United States. email@example.com
Telephone: +1-215-4568543 Fax: +1-215-4567706
Received: December 31, 2010 Revised: June 2, 2011 Accepted: June 9, 2011 Published online: July 27, 2011
AIM: To evaluate the efficacy and tolerability of an extended treatment protocol and to determine the predictors of sustained virological response (SVR) after liver transplantation (LT).
METHODS: Between August 2005 and November 2008, patients with recurrent hepatitis C virus (HCV) after LT were selected for treatment if liver biopsy showed at least grade 2 inflammation and/or stage 2 fibrosis. All patients were to receive pegylated interferon (PEG)/regimens combining ribavirin (RBV) for an additional 48 wk after HCV undetectability.
RESULTS: Extended protocol treatment was initiated in thirty patients. Overall, 73% had end of treatment response and 60% had SVR. Nineteen patients completed treatment per protocol, of them, sixteen (84%) had end of treatment response, and fourteen (74%) achieved SVR. Both early virological response and 24-week virological response were individually associated with SVR but this association was not significant on multivariate analysis. Eleven patients (37%) discontinued therapy due to adverse effects. Cytopenias were the most common and most severe adverse effect, and required frquent growth factor use, dose adjustments and treatment cessations. The risk of rejection was not increased.
CONCLUSION: Recurrent HCV after LT can be safely treated with extended virological response-guided therpy using PEG/RBV, but requires close monitoring for treatment-related adverse effects, particularly cytopenias.
Citation: Hashemi N, Araya V, Tufail K, Thummalakunta L, Feyssa E, Azhar A, Niazi M, Ortiz J. An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation. World J Hepatol 2011; 3(7): 198-204
Hepatitis C virus (HCV)-related end-stage liver disease is the leading indication of liver transplantation (LT) in the United States and Europe. HCV recurrence after LT is almost universal and occurs early, with histological recurrence observed in up to 70% of patients during the first year after LT. Cirrhosis develops in up to 30% of transplant recipients after 5 years with persistant HCV viremia, and may be associated with graft failure and the need for re-transplantation. This leads to lower patient survival rates compared to non-HCV transplant recipients. Eradicating HCV using antiviral therapy improves patient and graft survival[5-7].
Regimens combining ribavirin (RBV) with pegylated interferon (PEG) report rates of sustained virological response (SVR), ranging from 28% to 45% with up to 48 wk of treatment[8-13]. Currently, there are no established guidelines to determine the timing and type of HCV treatment after LT. In general, the approach to the treatment of HCV after liver transplantation is similar to the pre-transplant protocol of 48 wk of treatment with viral kinetic evaluation at 12 and 24 wk[8,10-12].
Patients with recurrent HCV after LT are likely to be slow virological responders due to immunosuppression and, therefore, SVR after 48 wk of antiviral therapy is expected to be lower than in immune-competent HCV patients. A few centers have reported improved SVR rates after extending treatment to 72 wk or longer in partial early virological responders (Partial EVR)[14-16]. Partial EVR is currently defined as achieving a 2-log drop in the HCV RNA pre-treatment levels at 12 wk, but not achieving HCV RNA undetectability until after 24 wk of treatment. Based on these observations, in August 2005 we designed a viral kinetics-driven treatment protocol that extended PEG/RBV combination therapy in order to maintain viral undetectability for an additional 48 wk of therapy. Our aim was to evaluate the safety and efficacy of this approach in patients who had significant HCV recurrence after LT, as determined by protocol liver biopsies.
MATERIALS AND METHODS
This is an IRB approved study.
Consecutive patients with HCV post-LT who were treated between August 2005 and November 2008 were screened for their eligibility for this study. Six patients were unable to start treatment due to relocation (3), non-compliance (2), or death from early recurrent cirrhosis and sepsis (1). Treatment was initiated in 30 patients. Eligibility criteria were LT for HCV-related end-stage liver disease, the presence of HCV RNA in serum by polymerase chain reaction (PCR), and histologically-proven chronic hepatitis in the graft with at least grade 2 inflammation and/or stage 2 fibrosis on METAVIR scoring of protocol liver biopsies. Additionally, antiviral therapy was initiated if features of aggressive disease (portal fibrosis or moderate-severe necroinflammation) were present on clinically indicated liver biopsies that occurred outside protocol times within the first year. Patients were ineligible for this study if they had unresolved acute or chronic rejection, severe cardiovascular disease, a history of autoimmune disease, coexistent hepatitis B, unresolved biliary complications, active alcohol use, decompensated cirrhosis, renal transplantation, untreated major depression, uncontrolled diabetes, clinically significant retinopathy or thyroid dysfunction, hemoglobin < 10 g/dL, absolute neutrophil count < 1000/mm3, platelet < 60 000/mm3, creatinine clearance < 50 mL/min, or patient refusal. Erythropoietin was used preemptively to increase hemoglobin to more than 10 g/dL prior to treatment in otherwise suitable treatment candidates. Data collected and analyzed included the following: patient demographics, viral genotype, interval between LT and initiation of treatment, body mass index, histological features (grade and stage), immunosuppressive therapy used, HCV viral load at baseline and kinetics during therapy, adverse events, dose adjustments and discontinuation, and the need for hematopoietic growth factors. The previous treatment records for these patients were unavailable.
A liver biopsy was performed, as per protocol, in all patients at 6 mo after LT, and then annually, to evaluate for hepatitis recurrence and to exclude histologic evidence of graft rejection and other viral infections. Samples were evaluated for inflammation (grade) and fibrosis (stage) using the METAVIR scoring system. Histological assessment was carried out by our pathologists utilizing standard processing techniques and criteria. Patients who had histological evidence of cirrhosis underwent abdominal ultrasound and upper endoscopy to screen for hepatocellular carcinoma and varices, respectively.
Initial immunosuppression in all patients included a cal-cineurin inhibitor (tacrolimus or cyclosporine) and corti-costeroids. Mycophenolate mofetil was used either as part of the initial triple immunosuppressive regimen or added later as maintenance immunosuppression. If possible, prednisone was withdrawn over the first nine months after LT. No adjustments in immunosuppression took place after antiviral treatment had been initiated. Our practice of minimizing overall immunosuppression during the first year after LT was followed in all patients. Antiviral treatment was discontinued once rejection had been determined on histology, which was treated by increasing the calcineurin-inhibitor dose, with or without steroid use.
Serum HCV RNA was measured by a quantitative assay (COBAS AmpliPrep or TaqMan, Roche Diagnostics, sensitivity limit 600 IU/mL) at baseline. A qualitative assay (Roche, sensitivity limit 50 IU/mL) was used at week 4, 12, at end of treatment, and every 12 wk after the end of treatment. Rapid virological response (RVR) was defined as viral undetectability at week 4 of treatment. EVR was defined as 2-log drop in viral count at week 12 of treatment. End of treatment (EOT) response was defined as viral undetectability at end of treatment. SVR was defined as a negative qualitative HCV-RNA assay 24 wk after the end of therapy. High viral load was defined as HCV RNA of more than 800 000.
All patients were treated with Pegylated Interferon alpha 2a (Pegasys, Hoffman-La Roche, Inc. Nutley, NJ) and RBV. The initial dose of 180 mcg/week was used in patients who had transplants more than two years earlier and had an absolute neutrophil count (ANC) of > 1500/mm3. Otherwise, an escalating dose regimen starting at 90 mcg/week, increasing as tolerated to a full dose of 180 mcg/week over 8 wk, was used. RBV was started at a dose of 10 mg/kg per day in patients who had transplants more than 2 years earlier and was increased as tolerated to 13-15 mg/kg per day over 4 to 6 wk. If fewer than 2 years had elapsed after transplantation, the starting RBV dose was 8 mg/kg per day, which was slowly increased to 10 mg/kg per day over 4 to 6 wk, then to 13 to 15 mg/kg per day as tolerated and continued at the highest tolerable dose for the duration of therapy.
Regardless of genotype, all patients were treated for a minimum of 48 wk, even if they had undetectable viremia at week 4. Treatment was discontinued if virus was detectable at week 48.
Erythropoietin (40 000 units subcutaneously once a week) was used if hemoglobin dropped below 10 g/dL. Where there was no improvement, the RBV dose was de-creased. RBV was discontinued if hemoglobin fell below 8 g/dL. Patients who had hemoglobin < 8 g/dL or became symptomatic received blood transfusions. During the period of dose adjustment, hemoglobin was monitored weekly. Once the hemoglobin had been stabilized or increased by at least 1 g/dL with erythropoietin, RBV dosage was increased gradually as tolerated weekly, aiming for baseline hemoglobin of 10 g/dL and RBV dose of 13-15 mg/kg per day. Patients with ANC < 750/mm3 were treated with weekly granulocyte colony stimulating factor (G-CSF, Filgrastim 480 mcg subcutaneously) initially, and if there was no improvement, PEG dose was reduced or held. Dose escalation was attempted once ANC increased to 750/mm3. PEG dose was also reduced if platelet count was < 30 000/L and discontinued if platelet count was < 25 000/L. Antiviral therapy was also reduced or suspended for antidepressantrefractory depression or disabling fatigue.
Continuous variables were presented as median (range) or number (percentages) and analyzed with the Wilcoxon rank test. Categorical variables were expressed as percentages and compared with the Fisher’s exact test. P values less than 0.05 were considered statistically significant.
Baseline characteristics of the 30 patients are summarized in Table 1. The median age at inclusion was 56 years (38-70), 23 patients were male. Twenty-two patients (73%) were overweight (body mass index > 25 kg/m2) and seven (23%) were obese (body mass index > 30 kg/m2). The median time to treatment from LT was 40.5 mo (2-132). The HCV genotype was 1 in 23 patients (77%), 2 in 4 (13%), and 3 in 3 patients (10%). Three patients had histologic evidence of cirrhosis. There were no patients with evidence of fibrosing cholestatic hepatitis.
M: Male; F: Female. Overweight: Body mass index > 25 kg/m2; High HCV RNA > 800 000 IU/mL.
Overall twenty-two patients (73%) had EOT response and 18 patients (60%) had SVR. Nineteen patients completed treatment per protocol. Of these, 15 (79%) were aviremic at the end of therapy and 14 (74%) achieved SVR. Eleven patients were unable to complete treatment per protocol and discontinued prematurely at an average of 23 wk due to adverse effects (8 patients) or viral breakthrough (2 patients), and one patient stopped treatment on his own. Of these eleven patients, six (54%) achieved EOT response, and 4 (36%) achieved SVR. The difference between SVR rates among the patients who completed the treatment protocol and those who did not was not statistically significant (P = 0.052).
Viral kinetics and virologic response has been summarized in table 3. Six patients (21%) had undetectable virus at week 4 (RVR), and all of them achieved SVR. Among the 21 patients with EVR, 16 (76%) achieved SVR (P = 0.03), whereas only two of nine patients (22%) without EVR achieved SVR. Fifteen of eighteen patients (83%) with aviremia at week 24 achieved SVR (P = 0.008), whereas the other 3 patients relapsed. Five patients had detectable viremia at week 24, only one (20%) of them achieved SVR. Both early virological response (EVR) and 24-week virological response were individually associated with SVR but this association was not significant on multivariate analysis.
Baseline characteristics were compared between the SVR and non-SVR groups (Table 2). The probability of achieving SVR was not related to baseline serum HCV RNA level, genotype, histologic grade or stage, interval between LT and initiation of therapy, BMI, presence of diabetes, duration of steroid use, presence of CMV antibody and total duration of antiviral therapy. SVR rate was 57% in patients with genotype 1 and 71% in genotypes 2 or 3. Sixteen of the 19 patients who completed treatment per protocol were treated for 48 weeks after achieving aviremia. Fourteen (88%) patients in that group achieved SVR. The interval between initiation of therapy and viral eradication ranged between 4-36 wk.
Table 2 Comparison between SVR and Non-SVR groups.
Number of patients
Age, median (range)
M: F, n
13 : 5
9 : 3
Diabetes Mell-itus, n
Months from LT, median (range) High HCV RNA, n CMV anti- body positive, n Genotype 1: non 1, n Pre-Treatment biopsy, n Stage 0-1 Stage 2-3 Stage 4 Grade 0-1 Grade 2-3 Grade 4 Total weeks of treatment, median (range) Erythropoietin use, n (%) G-CSF use, n (%)
M: Male; F: Female; LT: Liver Transplantation; G-CSF: Granulocyte-colony stimulating factors; SVR: sunstianed virological response. Overweight: Body mass index > 25 kg/m2; High HCV RNA: > 800 000 IU/mL.
Tolerability and adverse events
Eleven (37%) patients failed to complete therapy, mostly due to treatment-related adverse events. Two (7%) patients developed moderate acute cellular rejection, one at week 2 and another at week 13. Treatment was discontinued and corticosteroids were used to treat both patients. Four (13%) patients discontinued therapy for anemia, one developed pancreatitis, another developed pneumonia requiring hospitalization, two had virological relapse, and one discontinued treatment on his own. Growth factors and transfusions were frequently used. Twenty-three patients (77%) required therapy with erythropoietin for anemia, twelve (40%) required G-CSF, and ten (33%) required blood transfusions. Dose reductions were also instituted frequently. PEG and RBV doses were reduced in four (13%) and twelve (40%) patients, respectively. One patient developed biopsy-proven de novo autoimmune hepatitis 12 mo after completing a 72-week course of therapy and achieving an SVR[17-20].
There was no incidence of chronic rejection.
Hepatitis C recurrence remains a major cause of graft loss after liver transplantation. Studies using the same treatment protocol as in the non-transplant population have reported a lower overall sustained virological response among patients who have undergone transplants. Treatment-related adverse effects in transplant recipients are also more severe and dose-limiting. Specifically, cytopenias are more pronounced, due to concurrent bone marrow toxicity from immunosuppression. Our treatment protocol was designed to overcome these obstacles by timing the start of treatment to the severity of HCV recurrence, as determined by protocol liver biopsies. To keep dosing as high as possible, we also used growth factors prophylactically with at risk patients, and to maximize the likelihood of response, we extended treatment to maintain 48 wk of viral undetectability.
Our rationale for prolonged treatment was based on the immune-competent experience, where extending treatment beyond 48 wk has led to improved SVR rates in slow responders[21,22] who were likely to be over represented after liver transplant. Compared to a recent single center, observational study treating recurrent HCV after LT for 48 wk after viral undetectability that reported 26% SVR, we observed an overall SVR rate of 60%. The reasons for this difference could be attributed to a lower percentage of patients with advanced disease, and a longer interval between transplant and antiviral treatment in our study, as well as possible differences in immunosuppression.
A more recent study by Schmidt et al, showed that virological response at week 24 has a high predictive value for SVR in patients with recurrent HCV after LT. Similarly, we found that EVR and the 24-week virological response are associated with SVR with a positive predictive value of 76% and 83%, respectively. Only one patient with persistent viremia at week 24 was able to achieve SVR, which suggests that the 24-week stopping rule in the non-transplant population may be applicable to transplanted patients. On the other hand, lack of EVR has a negative predictive value of 98% in the immune-competent population, and has become a treatment stopping point[23-25]. This was not observed in our transplanted cohort where two (22%) of the nine patients who had not achieved EVR, actually went on to achieve SVR. This confers a negative predictive value of 78%. Although the improved SVR rate in the per-protocol group was not statistically significant, our findings suggest that a viral response-guided therapy using this protocol may be considered in a select group of slow responders.
This extended treatment protocol is complex, highly individualized and demanding for both patients and health care providers. The cost in terms of personnel time, laboratory testing and medication use is high, and may be prohibitive for general use. We observed similar treatment-related adverse events leading to dose reduction or treat-ment cessation in 20%-66% of transplanted patients[15,16,24]. Despite the aggressive and pre-emptive use of growth factors and blood transfusions, we observed similar results in our group, where treatment was prematurely discontinued due to severe side effects, principally cytopenias in 37% of patients. Our acute rejection rate of 7% (2 patients) was within the previously reported range of 5%-20%[9,11,14,15].
Our study has several limitations inherent to a retrospective case series. First, we didn't have a comparison group, due to lack of complete virological data on other patients having had transplants who had received HCV treatment prior to the initiation of our current treatment protocol. Second, we cannot explain why 2 patients achieved an SVR after treatment for only a relatively short period. Third, post-treatment liver biopsy data was available in only 8 patients, so we could not examine the changes in liver histology to determine the beneficial effects of prolonged antiviral therapy, i.e., histological improvement or stability, beyond achievement of SVR. Our small number of patients with cirrhosis did not allow us to examine whether achievement of SVR is associated with prevention of hepatic decompensation. Finally, although our results showed a trend towards a positive association between extended treatment protocol and SVR, statistical significance could not be achieved, possibly due to the small sample size.
In conclusion, our single-center observational pilot study suggests that extended treatment protocols may be utilized for HCV recurrence after LT. A response-guided treatment approach that aims to achieve SVR in patients who have viral undetectability by week 24 of treatment is feasible. However, this approach requires intense monitoring, frequent growth factor use and comes at a high cost, both in personnel and medical expense. Further studies comparing extended treatment protocols to standard 48 wk therapy can be helpful to determine the adequate duration of treatment for recurrent HCV after LT before extended treatment can be recommended unequivocally. It also remains to be seen whether the imminent addition of the direct acting antivirals to our armamentarium of treatment for HCV will obviate the need for extended antiviral therapy after LT, as more patients could potentially achieve desirable viral kinetics earlier in the treatment.
Hepatitis C virus (HCV)-related end-stage liver disease is the leading indication of liver transplantation (LT) in the United States and Europe. HCV recurrence after LT is almost universal and occurs early. Cirrhosis develops in up to 30% of transplant recipients after 5 years with persistant HCV viremia, and may be associated with graft failure and need for re-transplantation. Patients with recurrent HCV after LT are likely to be slow virological responders due to immunosuppression and, therefore, SVR after 48 wk of antiviral therapy is expected to be lower than immune-competent HCV patients.
It has been reported that a few centers have improved SVR rates after extending treatment to 72 wk or longer in partial early virological responders (Partial EVR). Partial EVR is currently defined as achieving a 2-log drop in the HCV RNA pre-treatment levels at 12 wk but not achieving HCV RNA undetectability until 24 wk of treatment.
Innovations and breakthroughs
Our single-center observational pilot study suggests that extended treatment protocols may be utilized for HCV recurrence after LT. A response-guided treatment approach that aims to achieve SVR in patients who have viral undetectability by week 24 of treatment is feasible.
This treatment protocol can be applied to patients who have HCV recurrence after LT to achieve SVR and decrease the incidence of graft loss.
“Viral breakthrough” is when the patient goes from undetectable to detectable viral loads while undergoing treatment. “Virological relapse” is when a patient has an undetectable virus at the end of treatment, but also has a detectable viral load after the treatment stops.
The authors describe their experience using an extended treatment protocol for recurrent hepatitis C after liver transplantation. Since hepatitis C invariably recurs after transplant and the treatment options are limited, this study is significant and adds important data to the literature.
Peer reviewers: Rachel Mary Hudacko, MD, Department of Pathology & Laboratory Medicine, Medical Education Building, Room 212, Robert Wood Johnson Medical School, 1 Robert Wood Johnson Place, New Brunswick, NJ 08901, United States; Iryna S Hepburn, MD, Gastroenterology and Hepatology, Medical College of Georgia, Augusta, GA1205 Sumter Landing Lane, Evans, GA 30809, United States
S- Editor Zhang HN L- Editor Herholdt A E- Editor Zhang L
Annual report of the US Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network Data: 1988-1994. United Network for Organ Sharing and the Division of Organ Transplantation, Bureau of Health Resources Development. In: Richmond; 1994;.
Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients.Liver Transpl. 2003;9:S28-S34.
Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R. Long-term outcome of hepatitis C infection after liver transplantation.N Engl J Med. 1996;334:815-820.
Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation.Gastroenterology. 2002;122:889-896.
Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, Rosen CB, Heimbach JK, Charlton MR. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection.Am J Transplant. 2008;8:2426-2433.
Bizollon T, Pradat P, Mabrut JY, Chevallier M, Adham M, Radenne S, Souquet JC, Ducerf C, Baulieux J, Zoulim F. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.Am J Transplant. 2005;5:1909-1913.
Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation.Am J Transplant. 2008;8:679-687.
Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, Garcia-Garzon S, Moreno A, Boullosa-Graña E, Rubio-Gonzalez EE. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.Am J Transplant. 2006;6:2348-2355.
Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, Rayón JM, Berenguer J. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.Liver Transpl. 2006;12:1067-1076.
Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, Fuertes A, Abradelo M, Lumbreras C, Moreno E. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.Liver Transpl. 2006;12:1805-1812.
Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.Liver Transpl. 2008;14:53-58.
Schmidt SC, Bahra M, Bayraktar S, Berg T, Schmeding M, Pratschke J, Neuhaus P, Neumann U. Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon.Dig Dis Sci. 2010;55:2063-2069.
Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, Duclos-Vallee JC, Castaing D, Samuel D. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.Liver Transpl. 2008;14:1766-1777.
Walter T, Scoazec JY, Guillaud O, Hervieu V, Chevallier P, Boillot O, Dumortier J. Long-term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: biochemical, virological, and histological impact.Liver Transpl. 2009;15:54-63.
Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.Transplantation. 2004;77:190-194.
Karasu Z, Akay S, Yilmaz F, Akarca U, Ersoz G, Gunsar F, Kilic M. A pilot study: longer duration of posttransplant hepatitis C virus therapy may increase the sustained response rate.Transplant Proc. 2009;41:3806-3809.
Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, Mor E, Bodian C, Guy SR, Schwartz ME. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation.Hepatology. 1998;28:831-838.
Singh N, Gayowski T, Wannstedt CF, Shakil AO, Wagener MM, Fung JJ, Marino IR. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial.Transplantation. 1998;65:82-86.
Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, García-Herola A, Olaso V, De Juan M, Gobernado M. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.Hepatology. 1999;29:250-256.
Mukherjee S, Lyden E. Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.Liver Int. 2006;26:529-535.
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update.Hepatology. 2009;49:1335-1374.
Berenguer M, Aguilera V, Prieto M, Ortiz C, Rodríguez M, Gentili F, Risalde B, Rubin A, Cañada R, Palau A. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis.Liver Transpl. 2009;15:738-746.
Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, Morelli MC, Piscaglia F, Tamè M, Pinna AD. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation.Liver Transpl. 2009;15:782-789.
Narayanan Menon KV, Poterucha JJ, El-Amin OM, Burgart LJ, Kremers WK, Rosen CB, Wiesner RH, Charlton M. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.Liver Transpl. 2002;8:623-629.
Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.Hepatology. 2007;46:1688-1694.
Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.Gastroenterology. 2006;130:1086-1097.